Page 12 - தேசிய கொடுக்கப்படுவதுடன் மருந்து பட்டியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sanofi continued its growth trajectory Strong increase in Q1 2021 business EPS(1) at CER

Sanofi continued its growth trajectory Strong increase in Q1 2021 business EPS(1) at CER
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomFrance generalPaul hudsonRegeneron mabsDaiichi sankyoBiond biologicsGroup strategyUnited state biomedical advanced researchGroupb vaccineInternational society on thrombosisUs district courtResearch developmentSanofi business servicesCommittee for orphan medicinal productsIndustrial affairs

Sanofi (NYSE:SNY), Merck & Company, Inc (NYSE:MRK) - Sanofi Shares Rise On Q1 Sales Boosted By Dupixent Franchise; Plans To Restart Haemophilia Study With Fitusiran

Sanofi (NYSE:SNY), Merck & Company, Inc (NYSE:MRK) - Sanofi Shares Rise On Q1 Sales Boosted By Dupixent Franchise; Plans To Restart Haemophilia Study With Fitusiran
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Sanofi pompeRegeneron pharmaceuticals incGlaxosmithkline plcMerck coNational reimbursement drug listகிளாக்சோஸ்மித்க்லைன் ப்ல்மெர்க் இணைதேசிய கொடுக்கப்படுவதுடன் மருந்து பட்டியல்

Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study

Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan franciscoRuihua xuJunshi biosciencesEli lillyInstitute of microbiology chinese academy scienceIr teamDrug administrationData monitoring committeeSun yat sen university cancer hospitalNational reimbursement drug listNational medical products administrationPr teamIndependent data monitoring committeeProgression free survivalOverall survival

Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study

United statesSan franciscoRuihua xuJunshi biosciencesJunshi bioscienceszhiEli lillySolebury troutbobInstitute of microbiology chinese academy scienceContact informationir teamDrug administrationData monitoring committeeSun yat sen university cancer hospitalNational reimbursement drug listNational medical products administrationPr teamIndependent data monitoring committee

Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study | Comunicados | Edición USA

22 abr 2021 Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study SHANGHAI, China, April 22, 2021 (GLOBE NEWSWIRE) Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the Independent Data Monitoring Committee (IDMC) has determined that toripalimab in combination with paclitaxel/cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma (ESCC) has reached its pre-specified primary endpoints of Progression Free Survival (PFS) and Overall Survival (OS) at the interim analysis of the randomized, double-blind, placebo-controlled, multi-center, phase III clinical study “JUPITER-06” (Clinicaltrials.gov identifier: NCT03829969). Junshi Biosciences will communicate with the regulatory authorities regarding the

United statesSan franciscoRuihua xuJunshi biosciencesEli lillyInstitute of microbiology chinese academy scienceIr teamDrug administrationData monitoring committeeSun yat sen university cancer hospitalNational reimbursement drug listNational medical products administrationPr teamFirst line treatmentIndependent data monitoring committeeProgression free survival